Varex Imaging Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Varex Imaging Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 27, 2024 | $811.00M | Nov 19, 2024 |
| FY2024 | Sep 29, 2023 | $893.40M | Nov 19, 2024 |
| FY2024 | Sep 30, 2022 | $859.40M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $818.10M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | $738.30M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $780.60M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $773.40M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $698.10M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $620.10M | Nov 27, 2018 |
| FY2017 | Oct 2, 2015 | $632.30M | Dec 13, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $844.60M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $811.00M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $893.40M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $859.40M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $818.10M | Nov 16, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $290.50M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $256.90M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $290.30M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $283.50M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $271.50M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | $190.20M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $256.70M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $253.90M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $253.50M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $248.40M | Nov 27, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | ($70.30M) | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | ($48.80M) | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $47.40M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $30.30M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $17.40M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | ($57.90M) | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $15.50M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $27.50M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $51.60M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $68.50M | Nov 27, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | ($27.80M) | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $32.10M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $77.10M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $88.20M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $74.10M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | ($33.70M) | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $45.70M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $44.50M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $83.70M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $109.10M | Nov 27, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $91.10M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $87.00M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $84.80M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $77.00M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $71.90M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | $78.90M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $78.10M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $83.00M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $67.30M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $53.50M | Nov 27, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $133.30M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $137.80M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $128.40M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $118.30M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $125.50M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | $142.20M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $128.10M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $123.40M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $102.50M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $85.80M | Nov 27, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $41.70M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $47.30M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $108.40M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $16.90M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $92.60M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | $13.20M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $71.90M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $85.30M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $75.20M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $74.20M | Nov 27, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $22.90M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $26.90M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $20.70M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $21.30M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $15.10M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | $23.50M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $19.80M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $20.40M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $20.20M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $28.90M | Nov 27, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $1.11B | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $1.21B | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $1.25B | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $1.18B | Nov 16, 2023 |
| FY2022 | Oct 1, 2021 | $1.15B | Nov 18, 2022 |
| FY2021 | Oct 2, 2020 | $1.14B | Nov 19, 2021 |
| FY2020 | Sep 27, 2019 | $1.04B | Nov 30, 2020 |
| FY2019 | Sep 28, 2018 | $987.90M | Dec 20, 2019 |
| FY2018 | Sep 29, 2017 | $1.04B | Nov 27, 2018 |
| FY2017 | Sep 30, 2016 | $622.40M | Dec 13, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $620.80M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $670.40M | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $668.60M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $637.70M | Nov 16, 2023 |
| FY2022 | Oct 1, 2021 | $651.00M | Nov 18, 2022 |
| FY2021 | Oct 2, 2020 | $673.70M | Nov 19, 2021 |
| FY2020 | Sep 27, 2019 | $580.20M | Nov 30, 2020 |
| FY2019 | Sep 28, 2018 | $548.50M | Dec 20, 2019 |
| FY2018 | Sep 29, 2017 | $649.90M | Nov 27, 2018 |
| FY2017 | Sep 30, 2016 | $86.10M | Dec 13, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $472.60M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $529.10M | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $567.70M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $533.40M | Nov 16, 2023 |
| FY2022 | Oct 1, 2021 | $483.30M | Nov 18, 2022 |
| FY2021 | Oct 2, 2020 | $451.70M | Nov 19, 2021 |
| FY2020 | Sep 27, 2019 | $444.90M | Nov 30, 2020 |
| FY2019 | Sep 28, 2018 | $426.20M | Dec 20, 2019 |
| FY2018 | Sep 29, 2017 | $379.00M | Nov 27, 2018 |
| FY2017 | Sep 30, 2016 | $526.00M | Dec 13, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $198.40M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $291.00M | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $288.50M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $284.50M | Nov 16, 2023 |
| FY2022 | Oct 1, 2021 | $292.20M | Nov 18, 2022 |
| FY2021 | Oct 2, 2020 | $293.10M | Nov 19, 2021 |
| FY2020 | Sep 27, 2019 | $290.80M | Nov 30, 2020 |
| FY2019 | Sep 28, 2018 | $243.60M | Dec 20, 2019 |
| FY2018 | Sep 29, 2017 | $241.90M | Nov 27, 2018 |
| FY2017 | Sep 30, 2016 | $74.70M | Dec 13, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | ($5.90M) | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $64.40M | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $118.10M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $63.80M | Nov 16, 2023 |
| FY2022 | Oct 1, 2021 | $33.50M | Nov 18, 2022 |
| FY2021 | Oct 2, 2020 | $16.10M | Nov 19, 2021 |
| FY2020 | Sep 27, 2019 | $74.40M | Nov 30, 2020 |
| FY2019 | Sep 29, 2018 | $58.90M | Dec 20, 2019 |
| FY2019 | Sep 28, 2018 | $62.40M | Dec 20, 2019 |
| FY2018 | Sep 29, 2017 | $35.10M | Nov 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $145.00M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $168.70M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $152.60M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $89.40M | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | $144.60M | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | $100.60M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $29.90M | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | $51.90M | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | $83.30M | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | $36.50M | Nov 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $367.50M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $443.40M | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $442.60M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $414.40M | Nov 16, 2023 |
| FY2022 | Oct 1, 2021 | $434.50M | Nov 18, 2022 |
| FY2021 | Oct 2, 2020 | $455.30M | Nov 19, 2021 |
| FY2020 | Sep 27, 2019 | $395.10M | Nov 30, 2020 |
| FY2019 | Sep 28, 2018 | $389.80M | Dec 20, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | (1) | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | (1) | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | 1 | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | 0 | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | 0 | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | (1) | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | 0 | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | 0 | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | 1 | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | 1 | Nov 27, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | (1) | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | (1) | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | 1 | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | 0 | Nov 19, 2024 |
| FY2023 | Oct 1, 2021 | 0 | Nov 16, 2023 |
| FY2022 | Oct 2, 2020 | (1) | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | 0 | Nov 19, 2021 |
| FY2020 | Sep 28, 2018 | 0 | Nov 30, 2020 |
| FY2019 | Sep 29, 2017 | 1 | Dec 20, 2019 |
| FY2018 | Sep 30, 2016 | 1 | Nov 27, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | 41.69M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | 41.09M | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | 40.53M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | 40.09M | Nov 16, 2023 |
| FY2022 | Oct 1, 2021 | 39.44M | Nov 18, 2022 |
| FY2021 | Oct 2, 2020 | 39.06M | Nov 19, 2021 |
| FY2020 | Sep 27, 2019 | 38.37M | Nov 30, 2020 |
| FY2019 | Sep 28, 2018 | 38.03M | Dec 20, 2019 |
| FY2018 | Sep 29, 2017 | 37.63M | Nov 27, 2018 |